Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD

DMM Disease Models and Mechanisms

Volumn 7, Issue 12, 2014, Pages 1385-1395

  Wang, Qi ^a,c   Xiao, Bing ^a,c   Cui, Shuqin ^b   Song, Hailong ^a   Qian, Yanjing ^a,c   Dong, Lin ^a,c   An, Haiting ^a,c   Cui, Yanqiu ^a   Zhang, Wenjing ^a,c   He, Yi ^a,c   Zhang, Jianliang ^a,c   Yang, Jian ^a,c   Zhang, Feilong ^a,c   Hu, Guanzheng ^a,c   Gong, Xiaoli ^a,c   Yan, Zhen ^d   Zheng, Yan ^a,c   Wang, Xiaomin ^a,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b DEZHOU UNIVERSITY   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

5XFAD mice; Alzheimer's disease; Amyloid ; BACE1; Inflammation; Triptolide

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; PRESENILIN 1; TRIPTOLIDE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; BACE1 PROTEIN, MOUSE; DITERPENE; EPOXIDE; IMMUNOSUPPRESSIVE AGENT; PHENANTHRENE DERIVATIVE; PLANT EXTRACT; SECRETASE;

5XFAD MOUSE; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NONHUMAN; PERFORMANCE; PROTEIN EXPRESSION; PROTEIN PROCESSING; SPATIAL LEARNING; ANIMAL; BRAIN; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; LEARNING; MAZE TEST; MEMORY; METABOLISM; MUTATION; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS; TRIPTERYGIUM WILFORDII;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; DISEASE MODELS, ANIMAL; DITERPENES; EPOXY COMPOUNDS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEARNING; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PHENANTHRENES; PLANT EXTRACTS;

EID: 84919638385     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.018218     Document Type: Article

References (37)

1. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D. and Jones, E. (2011). Alzheimer's disease. Lancet 377, 1019-1031.
2. Braak, H. and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
3. Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C. et al. (2012). Drug repositioning for Alzheimer's disease. Nat. Rev. Drug Discov. 11, 833-846.
4. Goedert, M. and Spillantini, M. G. (2006). A century of Alzheimer's disease. Science 314, 777-781.
5. Gong, Y., Xue, B., Jiao, J., Jing, L. and Wang, X. (2008). Triptolide inhibits COX-2 expression and PGE2 release by suppressing the activity of NF-kappaB and JNK in LPS-treated microglia. J. Neurochem. 107, 779-788.
6. Hardy, J. and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
7. He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R. and Shen, Y. (2007). Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J. Cell Biol. 178, 829-841.
8. Huang, Y. and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
9. Jiao, J., Xue, B., Zhang, L., Gong, Y., Li, K., Wang, H., Jing, L., Xie, J. and Wang, X. (2008). Triptolide inhibits amyloid-beta1-42-induced TNF-alpha and IL-1beta production in cultured rat microglia. J. Neuroimmunol. 205, 32-36.
10. Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J. et al. (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99.
11. Lee, H. F., Lee, T. S. and Kou, Y. R. (2012). Anti-inflammatory and neuroprotective effects of triptolide on traumatic brain injury in rats. Respir. Physiol. Neurobiol. 182, 1-8.
12. Li, F. Q., Cheng, X. X., Liang, X. B., Wang, X. H., Xue, B., He, Q. H., Wang, X. M. and Han, J. S. (2003). Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons. Exp. Neurol. 179, 28-37.
13. Li, F. Q., Lu, X. Z., Liang, X. B., Zhou, H. F., Xue, B., Liu, X. Y., Niu, D. B., Han, J. S. and Wang, X. M. (2004a). Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. J. Neuroimmunol. 148, 24-31.
14. Li, R., Lindholm, K., Yang, L. B., Yue, X., Citron, M., Yan, R., Beach, T., Sue, L., Sabbagh, M., Cai, H. et al. (2004b). Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. USA 101, 3632-3637.
15. Liu, P. and Bilkey, D. K. (2001). The effect of excitotoxic lesions centered on the hippocampus or perirhinal cortex in object recognition and spatial memory tasks. Behav. Neurosci. 115, 94-111.
16. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. and Kivipelto, M. (2010). Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702-716.
17. Morris, R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47-60.
18. Mucke, L. and Selkoe, D. J. (2012). Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2, a006338.
19. Nie, J., Zhou, M., Lü, C., Hu, X., Wan, B., Yang, B. and Li, Y. (2012). Effects of triptolide on the synaptophysin expression of hippocampal neurons in the AD cellular model. Int. Immunopharmacol. 13, 175-180.
20. Nussbaum, R. L. and Ellis, C. E. (2003). Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348, 1356-1364.
21. O'Keefe, J. and Dostrovsky, J. (1971). The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely-moving rat. Brain Res. 34, 171-175.
22. Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L. et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140.
23. Pruessmeyer, J. and Ludwig, A. (2009). The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin. Cell Dev. Biol. 20, 164-174.
24. Reitz, C., Brayne, C. and Mayeux, R. (2011). Epidemiology of Alzheimer disease. Nat Rev Neurol. 7, 137-152.
25. Selkoe, D. J. (1993). Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 16, 403-409.
26. Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
27. Soundararajan, R., Sayat, R., Robertson, G. S. and Marignani, P. A. (2009). Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. Cancer Biol. Ther. 8, 2054-2062.
28. Titov, D. V., Gilman, B., He, Q. L., Bhat, S., Low, W. K., Dang, Y., Smeaton, M., Demain, A. L., Miller, P. S., Kugel, J. F. et al. (2011). XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat. Chem. Biol. 7, 182-188.
29. Wang, H., Li, R. and Shen, Y. (2013a). β-Secretase: its biology as a therapeutic target in diseases. Trends Pharmacol. Sci. 34, 215-225.
30. Wang, J., Shi, Z. Q., Xu, X., Xin, G. Z., Chen, J., Qi, L. W. and Li, P. (2013b). Triptolide inhibits amyloid-β production and protects neural cells by inhibiting CXCR2 activity. J. Alzheimers Dis. 33, 217-229.
31. Xue, B., Jiao, J., Zhang, L., Li, K. R., Gong, Y. T., Xie, J. X. and Wang, X. M. (2007). Triptolide upregulates NGF synthesis in rat astrocyte cultures. Neurochem. Res. 32, 1113-1119.
32. Yang, L. B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X. L., Beach, T., Sue, L., Wong, P., Price, D. et al. (2003). Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9, 3-4.
33. Zheng, Y., Wang, Q., Xiao, B., Lu, Q., Wang, Y. and Wang, X. (2012). Involvement of receptor tyrosine kinase Tyro3 in amyloidogenic APP processing and β-amyloid deposition in Alzheimer's disease models. PLoS ONE 7, e39035.
34. Zheng, Y., Zhang, W. J. and Wang, X. M. (2013). Triptolide with potential medicinal value for diseases of the central nervous system. CNS Neurosci. Ther. 19, 76-82.
35. Zhou, H. F., Niu, D. B., Xue, B., Li, F. Q., Liu, X. Y., He, Q. H., Wang, X. H. and Wang, X. M. (2003). Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures. Neuroreport 14, 1091-1095.
36. Zhou, H. F., Liu, X. Y., Niu, D. B., Li, F. Q., He, Q. H. and Wang, X. M. (2005). Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol. Dis. 18, 441-449.
37. Zhou, Z. L., Yang, Y. X., Ding, J., Li, Y. C. and Miao, Z. H. (2012). Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat. Prod. Rep. 29, 457-475.